Literature DB >> 28162114

Surgical closure of multiple large apical ventricular septal defects: how we do it.

Carolina Perez-Negueruela1, Joan Carretero1, Javier Mayol1, José M Caffarena1.   

Abstract

The management of apical ventricular septal defects continues to be challenging because of the difficulty in achieving a complete closure without a left apical ventriculotomy. In this study, we present our innovative technique of closing multiple and/or large muscular apical ventricular septal defects through a right atriotomy. We operated three patients with multiple apical muscular trabecular ventricular septal defects ("Swiss cheese") using a technique that involved exclusion of the right ventricular apex. Their ages ranged between 2 months and 13 years. The VSDs were approached through right atriotomy. The trans right atrial approach using a 5-0 polypropylene purse-string suture or a two-patch procedure is a novel method of closing large apical ventricular septal defects. It was found to be effective with no persistent residual defects and did not have the disadvantages of a ventriculotomy.

Entities:  

Keywords:  Swiss cheese; Ventricular septal defect; congenital cardiac surgery; multiple apical ventricular septal defects

Mesh:

Year:  2017        PMID: 28162114     DOI: 10.1017/S1047951116001517

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  2 in total

1.  Percardiac closure of large apical ventricular septal defects in infants: Novel modifications and mid-term results.

Authors:  Geoffrey J Changwe; Li Hongxin; Hai-Zhou Zhang; Guo Wenbin; Fei Liang; Xing-Xu Cao; Shan-Liang Chen
Journal:  J Card Surg       Date:  2021-01-27       Impact factor: 1.620

2.  Biventricular surgical repair of "Swiss Cheese" ventricular septal defects with two-patch and right ventricle apex excluding technique: preliminary experience and clinical results.

Authors:  Qin Wu; Lei Shi; Rui Chen; Quansheng Xing
Journal:  J Cardiothorac Surg       Date:  2021-03-20       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.